Bluejay Diagnostics filings document the company’s medical diagnostics business, Nasdaq-listed common stock, and disclosures tied to development of the Symphony™ near-patient testing platform. Form 8-K reports cover corporate updates, financial condition items, Regulation FD disclosures, SYMON clinical-study updates, conference-related product disclosures, manufacturing readiness, and capitalization matters involving warrants and private placements.
The company’s proxy materials describe annual meeting proposals, voting procedures, board and governance matters, and stockholder approval topics. Bluejay’s filings also identify it as an emerging growth company and include formal disclosures on material agreements, registered securities, risk-relevant development activities, and capital-structure changes such as reverse stock splits and warrant exercises.
Bluejay Diagnostics, Inc. (BJDX) completed establishment of a manufacturing site for Symphony™ cartridges, meeting a contractual milestone under its amended license agreement with Toray Industries, Inc. ahead of the October 23, 2026 deadline. Bluejay notified Toray that it had fulfilled its obligation to substantially complete the site; SanyoSeiko Co., Ltd. in Japan is the site established under that agreement.
Bluejay’s manufacturing strategy also includes a U.S. manufacturing relationship with ALURIS Sciences. The Symphony™ IL-6 Test has not been cleared or approved by the FDA and is not available for commercial clinical use in the United States.
Bluejay Diagnostics, Inc. (BJDX) reported preliminary baseline characteristics from its SYMON-II clinical validation study, which is evaluating IL-6 in relation to 28-day mortality risk in patients with sepsis and septic shock. The analysis includes 777 evaluable patients: 637 28-day survivors and 140 non-survivors, with an approximately 18% overall 28-day mortality rate. 39.5% met Sepsis-3 criteria for septic shock.
Septic shock was present at baseline in 56.4% of non-survivors and 35.8% of survivors. Bluejay said these baseline characteristics do not establish the test’s prognostic performance, clinical utility, sensitivity, specificity, or regulatory acceptability; analyses of IL-6 measurements and their relationship to mortality are continuing. The Symphony IL-6 Test has not been FDA cleared or approved and is not currently available for commercial clinical use in the United States. Bluejay plans to use SYMON-II to support a 510(k) application.
Bluejay Diagnostics, Inc. (BJDX) entered into a Distribution, Co-Marketing & Strategic Partnership Agreement with Lovell Government Services, Inc., a Service-Disabled Veteran-Owned Small Business, to distribute Bluejay’s medical diagnostic products to U.S. federal, state and local government customers following applicable FDA clearance or other required regulatory authorization.
Lovell receives a non-exclusive right to list and resell Bluejay’s products in open-market government procurements and a sole and exclusive right for federal procurement opportunities requiring or favoring SDVOSB set-aside status, including VA, DoD and IHS channels via vehicles such as VA Federal Supply Schedule, GSA Advantage, MAS, ECAT and DAPA. Bluejay paid a one-time $5,500 establishment fee; Lovell earns an approximate 15% distribution fee on gross sales through its federal catalogs and an additional 2% fee on sales via DAPA prime vendors, with these fees added to Bluejay’s cost of goods sold rather than reducing its profit margin.
The agreement runs for an initial two-year term with automatic one-year renewals unless either party gives 90 days’ notice of non-renewal. Lovell must remit payment within three business days after receiving funds from the government customer or within 30 days of a valid invoice, whichever is later; unpaid undisputed amounts accrue interest at up to 18% per annum. Either party may terminate immediately for specified adverse events, such as certain sanctions, bankruptcy, or a final judgment over $100,000, or for uncured defaults after 30 days’ notice. A co-marketing framework supports joint outreach to federal healthcare stakeholders as Bluejay advances toward potential commercialization.
Bluejay Diagnostics, Inc. (BJDX) reported that director Fred S. Zeidman received a grant of 100,000 stock options on 2026-08-17. These options have an exercise price of $2.075 per share and expire on 2031-08-17. They vest on the first anniversary of the grant date and are not exercisable unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. Following this grant, Zeidman holds 100,000 options directly.
Bluejay Diagnostics, Inc. (BJDX) reported that director Wurth Douglas Clark received a grant of stock options for 100,000 shares of common stock. The options have an exercise price of $2.075 per share, expire on August 17, 2031, and are currently out-of-the-money. They vest on the first anniversary of the grant date and cannot be exercised unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.
Bluejay Diagnostics, Inc. (BJDX) reported that director Svetlana Dey received a grant of 100,000 stock options to purchase common stock at an exercise price of $2.075 per share. The options vest and become exercisable on the first anniversary of the grant, but cannot be exercised unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. These options expire on August 17, 2031, and following this grant Dey holds 100,000 options directly.
Bluejay Diagnostics, Inc. (symbol: BJDX) is the issuer of record for a Form 4 filing submitted to the SEC.
Bluejay Diagnostics, Inc. (BJDX) reported that director Donald R. Chase received a grant of 100,000 stock options to purchase common stock. The options have an exercise price of $2.075 per share, expire on August 17, 2031, and vest on the first anniversary of the grant date. According to the award terms, the options are not exercisable unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of Bluejay Diagnostics, Inc. common stock. They disclose beneficial ownership of 142,728 shares of common stock, representing 9.99% of the class. All 142,728 shares are reported with shared voting and shared dispositive power, and no shares with sole voting or dispositive power.
The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager under an Investment Management Agreement, and Steven Boyd may be deemed to share beneficial ownership as managing member of Armistice Capital. The Master Fund has the right to receive dividends and sale proceeds on the reported securities.
Bluejay Diagnostics, Inc. has a significant shareholder group led by Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri. As of June 30, 2026, the reporting persons beneficially owned 107,722 shares of Bluejay common stock, representing 9.99% of the class.
The position consists of 65,000 shares of common stock and 42,722 shares issuable upon exercise of warrants, which are subject to a 9.99% beneficial ownership blocker. Ownership percentages are based on 1,034,715 shares outstanding as of May 4, 2026, plus the warrant shares. The reporting persons each have sole voting and dispositive power over the reported shares.